Posting this on behalf of the Campaigns Team
Kadcyla in Scotland – make your voice heard
The Scottish Medicines Consortium (SMC) provides advice to the NHS in Scotland about the use of new medicines.
The SMC are currently in the process of assessing Kadcyla (non-branded name of trastuzumab emtansine) for use in the NHS in Scotand and are currently inviting submissions from patient groups to feed into this process. The SMC are due to make a decision this Autumn.
As you may know, Kadclya is used to treat people with HER2 positive secondary breast cancer or regional recurrence (where surgery is not possible), who have already had trastuzumab and chemotherapy drugs called taxanes, either together or separately.
Kadcyla can mean those facing limited treatment options live longer and with fewer severe side effects, such as being sick, vastly improving their quality of life.
We are working alongside other breast cancer charities to make a submission to the SMC. We are keen to increase the patient voice in our submission and are seeking input from:
- people affected by secondary breast cancer
- people affected by secondary breast cancer who are currently enrolled on trials of trastuzumab emtansine
- those around them – carers, family members and friends
We would like to hear your views on the impact having access to this drug could have, both for people with secondary breast cancer and those around them.
Please email campaigns@breastcancercare.org.uk to tell us your views. We will use this for our response and keep you updated.
Many thanks
Emma, The Policy & Campaigns team